Financings
Cheelcare Announces a Non-Brokered Private Placement to Raise up to $1.5 Million
Small-cap mobility device maker scales commercialization but relies on recurring capital raises to fund cash burn.
Executive Summary
- Cheelcare Inc. announced a non-brokered private placement to raise up to $1.5 million CAD by issuing up to 1,000,000 units at $1.50 per unit.
- Each unit consists of one common share and one-half of a common share purchase warrant.
- Warrants carry a $2.25 exercise price, a two-year term, and an acceleration clause if the TSXV share price reaches $3.00 for 10 consecutive trading days.
- Proceeds are earmarked for general working capital, product development, and commercialization activities.
- The offering is subject to TSX Venture Exchange approval and customary closing conditions, with a statutory hold period of four months and one day.
Material Impact
- The private placement is a standard small-cap capital raise designed to extend operating runway amid active commercialization and manufacturing scale-up.
- The $1.50 unit price aligns with the stock's recent trading low ($1.51 on June 10), indicating a modest discount typical of non-brokered placements.
- Direct dilution from the equity component is approximately 5% of outstanding shares, with additional potential dilution from warrant exercises.
- The financing does not alter the company's business model, product roadmap, or reimbursement status. It simply provides liquidity to fund the cash burn observed in recent quarters.
- Given the company's prior $1.0 million unsecured note closing in February 2026 and the tight cash position reported in March, this raise is operationally necessary but not transformative.
CHER · Price
Company Overview
- Cheelcare Inc. designs and manufactures mobility solutions, primarily the Companion power-assist device for manual wheelchairs and the Curio robotic complex-rehab power wheelchair.
- The company operates a B2B and B2C distribution model through a network of over 500 dealers globally, including major North American networks and over 20 U.S. Veterans Affairs medical centers.
- Recent operational milestones include the completion of a 16,000 sq ft manufacturing facility, pilot production of the Curio platform, and the achievement of 2,000 cumulative Companion unit sales.
- The business model relies on insurance reimbursement pathways (U.S. Medicare/Medicaid, Ontario ADP) to reduce private-pay barriers and drive predictable revenue growth.
More from Cheelcare Inc.
Jun 18, 2026 · 07:31